American Society of Clinical Oncology

SHERPA: White

People

  1. Rosenberg
    Rosenberg
  2. Bajorin
    Bajorin
  3. Iyer
    Iyer
  4. Regazzi
    Regazzi
  5. Bochner
    Bochner
  6. Funt
    Funt
  7. Teo
    Teo
  8. Solit
    Solit
  9. Ostrovnaya
    Ostrovnaya
  10. Al-Ahmadie
    Al-Ahmadie

Groups

  1. Department of Medicine (182)
  2. Genitourinary Oncology Service (182)
  3. Solid Tumor Oncology Division (182)
  4. Surgery (38)
  5. Urology (38)
  6. GSK Faculty (36)
  7. Epidemiology and Biostatistics (32)
  8. Biostatistics Service (30)
  9. Human Oncology and Pathogenesis Program (29)
  10. Survivorship Research (23)
Search Within
  1. "Jonathan Rosenberg"
Formats
  1. Meeting Abstract (159)
  2. Journal Article (20)
  3. Correspondence (3)
Groups
  1. Department of Medicine (182)
  2. Genitourinary Oncology Service (182)
  3. Solid Tumor Oncology Division (182)
  4. Surgery (38)
  5. Urology (38)
  6. GSK Faculty (36)

More Groups

People
  1. Jonathan Rosenberg (182)
  2. Dean Bajorin (76)
  3. Gopakumar Iyer (57)
  4. Hikmat Al-Ahmadie (43)
  5. Ashley Regazzi (39)
  6. Bernard Bochner (36)

More People

Years
  1. 2023 (19)
  2. 2022 (19)
  3. 2021 (13)
  4. 2020 (22)
  5. 2019 (23)
  6. 2018 (22)

More Years

Publications
  1. Journal of Clinical Oncology (180)
  2. JCO Precision Oncology (1)
  3. Journal of Oncology Practice (1)

Results (182)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Defining hereditary upper tract urothelial carcinoma: Implications for genetic testing and clinical management
    Meeting Abstract

    Truong, H.; Sheikh, R.; Kemel, Y.; De Jesus Escano, M.; Khurram, A.; Reisz, P.; Lenis, A. T.; Goh, A. C.; Cha, E. K.; Bochner, B. H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Final results of a multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma
    Meeting Abstract

    Yip, W.; Coleman, J.; Wong, N. C.; Sjoberg, D. D.; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Pietzak, E. J.; Hakimi, A. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors
    Meeting Abstract

    Tang, M.; Garg, A.; Bonate, P.; Rosenberg, J. E.; Kadokura, T.; Yamada, A.; Fukushi, R.; Koibuchi, A.; Hanley, W. D.; Poondru, S.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC)
    Meeting Abstract

    Rosenberg, J. E.; Park, S. H.; Dao, T. V.; Castellano, D. E.; Li, J. R.; Mukherjee, S.; Howells, K.; Dry, H.; Lanasa, M. C.; Stewart, R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible
    Meeting Abstract

    Petrylak, D. P.; Flaig, T. W.; Mar, N.; Gourdin, T. S.; Srinivas, S.; Rosenberg, J. E.; Guseva, M.; Yu, Y.; Narayanan, S.; Hoimes, C. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Favorable toxicity of chemoradiation for muscle-invasive bladder cancer in elderly, frail patients
    Meeting Abstract

    Moore, A.; Zhang, Z.; Bochner, B. H.; Donahue, T. F.; Rosenberg, J. E.; Iyer, G.; Funt, S. A.; Bajorin, D. F.; Teo, M. Y.; Aggen, D. H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress)
    Meeting Abstract

    Hoimes, C. J.; Flaig, T. W.; Srinivas, S.; Mar, N.; Petrylak, D. P.; O'Donnell, P. H.; Bilen, M. A.; Sasse, C.; Yu, Y.; Birrenkott, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: A multicenter, single-arm, phase II trial
    Journal Article

    Funt, S. A.; Lattanzi, M.; Whiting, K.; Al-Ahmadie, H.; Quinlan, C.; Teo, M. Y.; Lee, C. H.; Aggen, D.; Zimmerman, D.; McHugh, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2
    Meeting Abstract

    McGregor, B. A.; Balar, A. V.; Rosenberg, J. E.; Van Der Heijden, M. S.; Park, S. H.; Lee, J. L.; Kojima, T.; Harrison, M. R.; Heath, E. I.; Stein, M. N.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Friedlander, T. W.; Milowsky, M. I.; Bilen, M. A.; Srinivas, S.; McKay, R. R.; Flaig, T. W.; Hoimes, C. J.; Balar, A. V.; Henry, E.; Petrylak, D. P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save